Clinical Value and Mechanism Exploration of Serum miR-379 in Obesity-Polycystic Ovary Syndrome
Lu Huang,Yujing Fu,Jinghong Cao,Jianjun Zhai
DOI: https://doi.org/10.2147/ijwh.s427997
2024-06-22
International Journal of Women s Health
Abstract:Lu Huang, Yujing Fu, Jinghong Cao, Jianjun Zhai Department of Obstetrics and Gynecology, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, People's Republic of China Correspondence: Jianjun Zhai, Department of Obstetrics and Gynecology, Beijing Tongren Hospital, Capital Medical University, NO.1 of Dongjiaominxiang Street, Dongcheng District, Beijing, 100730, People's Republic of China, Email Objective: As a common endocrine and metabolic disorder, polycystic ovary syndrome (PCOS) is mostly associated with an obese phenotype. The present research focuses on the clinical significance of miR-379 in obesity-PCOS and attempts to elucidate its potential mechanisms. Methods: Healthy individuals (n = 46), obesity-PCOS (n = 92), and non-obesity PCOS (n = 31) subjects were enrolled. Quantitative real-time polymerase chain reaction (qRT-PCR) was conducted to examine the level of serum miR-379. The receiver operating characteristic (ROC) curve and logistic regressions were applied to reveal the diagnostic significance. Dual luciferase reporters were performed to validate the targeting relationships. And cell count kit (CCK-8) assay was used to detect cell proliferation. Results: Serum miR-379 was highly expressed in PCOS patients ( P < 0.05), in especially obesity-PCOS patients. Higher miR-379 was associated with greater body mass index (BMI), higher bioavailable testosterone (bT), and greater insulin resistance (IR). Additionally, miR-379 was an independent risk factor for the development of obesity-PCOS. The sensitivity of miR-379 in identifying patients with obesity-PCOS from healthy or non-obesity-PCSO patients was 81.52% and 72.83%, and the specificity was 86.96% and 80.65%. Semaphorin 3 A (SEMA3A) was identified as a target of miR-379 and was reduced in the patients with obesity PCOS (P < 0.05). Inhibition of miR-375 reduced KGN proliferation, but this reduction was partially restored by silencing of SEMA3A ( P < 0.05). Conclusion: Elevated miR-379 assists the diagnosis of obesity-PCOS and regulates the proliferation of KGN by targeting SEMA3A engaged in disease development. Keywords: obesity, PCOS, miR-379, diagnostic, SEMA3A Polycystic ovarian syndrome (PCOS) is a heterogeneous disease, characterized by the symptoms of polycystic ovary, hyperandrogenemia, menorrhagia, amenorrhea, and other manifestations. PCOS could last the entire life of a woman and frequently occurs at childbearing age. Women with PCOS are prone to obesity, over half of PCOS patients show signs of obesity, and obesity in turn affects the onset and development of PCOS. Additionally, there is a vicious cycle between fat deposition and hyperandrogenemia in PCOS patients, which induces endocrine disturbance. 1 It was also believed that obesity could influence leptin levels and lead to corresponding resistance, which inhibits ovulation by affecting the interaction of insulin-like growth factors, follicle-stimulating hormone, and other factors. 2 Therefore, obesity PCOS has become an important research hot point. However, the diagnosis criteria of obesity PCOS have been constantly revised in controversy and there are no definite conclusions yet, due to the unclear etiology, and pathogenesis. The diagnosis of obesity PCOS is always confirmed after the exclusion of hyperandrogenemia- or ovarian dysfunction-related diseases. Therefore, it is an urgent need to explore reliable and effective diagnostic biomarkers for obesity PCOS. MicroRNAs (miRNAs) could bind with proteins and therefore negatively regulate the transcription and translation of target mRNAs. The function of miRNAs has been widely reported, especially for their roles in human diseases, miRNAs have been considered critical regulators in disease development. Previous studies speculated miRNAs were involved in the onset and regulate the progression of PCOS, where several potential biomarkers were identified, such as miR-199a-5p, 3 miR-98-3p, 4 and miR-130b-3p. 5 The identified candidate miRNAs always showed abnormal expression and could regulate cellular processes during PCOS development. Recently, a number of studies have been devoted to constructing expression profiling in PCOS aiming to explore more potential biomarkers, which lacked data confirmation. For example, Xiao et al established a miRNA expression profile in 75 PCOS women. The differentially expressed miRNAs were demonstrated to be correlated with the menstrual cycle, antral follicle count, and hormone level and showed significance in discriminating PCOS patients. 6 A previous sequencing study identified several hyperandrogenism-related abnormally expressed miRNAs in the follicular fluid of PCOS women, where miR-379 was included. 7</su -Abstract Truncated-
obstetrics & gynecology